Sandoz (SDZ.SW) reported first quarter net sales of $2.76 billion compared to $2.48 billion, prior year. Sandoz said its performance was in line with company expectations. The company confirmed its guidance for 2026.
Overall net sales were up by 3% at CC, and by 5% when excluding effect of adverse dynamics in anti-infective B2B business. Biosimilar net sales were up by 18% at CC, with generics net sales declining by 3% at CC. Underlying generics net sales declined by 1% at CC when excluding anti-infective B2B impact.
The company intends to publish half-year results on 5 August 2026.
For more earnings news, earnings calendar, and earnings for stocks, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Business News
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.